[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

James Flynn Biography and Net Worth

Major Shareholder of Mirum Pharmaceuticals

James Flynn is the Major Shareholder of Mirum Pharmaceuticals.

What is James E. Flynn's net worth?: The estimated net worth of James E. Flynn is at least $241.74 million as of November 11th, 2024. Flynn owns 5,274,735 shares of Mirum Pharmaceuticals stock worth more than $241,741,105 as of December 3rd. This net worth estimate does not reflect any other investments that Flynn may own. Learn More about James E. Flynn's net worth.
How do I contact James E. Flynn?: The corporate mailing address for Flynn and other Mirum Pharmaceuticals executives is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. Mirum Pharmaceuticals can also be reached via phone at (650) 667-4085 and via email at [email protected]. Learn More on James E. Flynn's contact information.
Has James E. Flynn been buying or selling shares of Mirum Pharmaceuticals?: James E. Flynn has not been actively trading shares of Mirum Pharmaceuticals in the last ninety days. Most recently, James E. Flynn sold 38,478 shares of the business's stock in a transaction on Monday, June 6th. The shares were sold at an average price of $25.01, for a transaction totalling $962,334.78. Following the completion of the sale, the insider now directly owns 1,540,190 shares of the company's stock, valued at $38,520,151.90. Learn More on James E. Flynn's trading history.
Who are Mirum Pharmaceuticals' active insiders?: Mirum Pharmaceuticals' insider roster includes Ian Clements (CFO), James Flynn (Major Shareholder), Christopher Peetz (Co-Founder, CEO and Director), and Pamela Vig (Insider). Learn More on Mirum Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Mirum Pharmaceuticals?: During the last twelve months, Mirum Pharmaceuticals insiders bought shares 4 times. They purchased a total of 4,345 shares worth more than $115,064.40. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 54,136 shares worth more than $1,738,025.44. The most recent insider tranaction occured on November, 14th when SVP Jolanda Howe sold 2,500 shares worth more than $117,750.00. Insiders at Mirum Pharmaceuticals own 22.9% of the company. Learn More about insider trades at Mirum Pharmaceuticals.
Information on this page was last updated on 11/14/2024.

James E. Flynn Insider Trading History at Mirum Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/6/2022	Sell	38,478	$25.01	$962,334.78	1,540,190
7/9/2021	Sell	99,325	$15.81	$1,570,328.25
7/6/2021	Sell	49,239	$16.20	$797,671.80
7/2/2021	Sell	10,599	$17.01	$180,288.99
7/22/2019	Buy	332,000	$15.00	$4,980,000.00

James E. Flynn Buying and Selling Activity at Mirum Pharmaceuticals

Mirum Pharmaceuticals Company Overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Today's Range

Now: $45.83

$45.46

$46.73

50 Day Range

MA: $40.93

$37.85

$46.65

2 Week Range

Now: $45.83

$23.14

$48.89

Volume

58,186 shs

Average Volume

549,686 shs

Market Capitalization

$2.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2